Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables - Net: 2023-2024

Historic Receivables - Net for BridgeBio Pharma (BBIO) over the last 2 years, with Dec 2024 value amounting to $4.7 million.

  • BridgeBio Pharma's Receivables - Net was N/A to $116.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.5 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2024, which is 169.67% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Receivables - Net is $4.7 million, which was up 169.67% from $1.8 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Receivables - Net high stood at $4.7 million for FY2024, and its period low was $1.8 million during FY2023.
  • For the 2-year period, BridgeBio Pharma's Receivables - Net averaged around $3.2 million, with its median value being $3.2 million (2023).
  • Data for BridgeBio Pharma's Receivables - Net shows a peak YoY spiked of 169.67% (in 2024) over the last 5 years.
  • BridgeBio Pharma's Receivables - Net (Yearly) stood at $1.8 million in 2023, then skyrocketed by 169.67% to $4.7 million in 2024.